1. "Alexander Drilon"
Formats
  1. Meeting Abstract (373)
  2. Journal Article (219)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (631)
  2. Solid Tumor Oncology Division (631)
  3. Thoracic Oncology (631)
  4. Department of Pathology and Laboratory Medicine (205)
  5. GSK Faculty (187)
  6. Human Oncology and Pathogenesis Program (156)

More Groups

People
  1. Alexander Drilon (631)
  2. Marc Ladanyi (121)
  3. Mark Kris (89)
  4. Maria Arcila (82)
  5. David Hyman (78)
  6. Bob Li (65)

More People

Years
  1. 2025 (16)
  2. 2024 (61)
  3. 2023 (67)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (77)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (631)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Selpercatinib in RET fusion-positive non-small cell lung cancer: Final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I/II trial
    Journal Article

    Gautschi, O.; Park, K.; Solomon, B. J.; Tomasini, P.; Loong, H. H.; De Braud, F.; Goto, K.; Peterson, P.; Barker, S.; Liming, K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors
    Journal Article

    Nykaza, I.; Murciano-Goroff, Y. R.; Desilets, A.; Harada, G.; Postow, M. A.; Callahan, M. K.; Lee, C. H.; Rudin, C. M.; Kelsen, D. P.; Stadler, Z. K.; more...
    The Oncologist (2025)

    Fulltext@MSK | Save
  • Barriers to publishing early phase clinical trials: The oncologists’ perspective
    Journal Article

    Lucassen, M. J. J.; Bergmann, P.; Husson, O.; Banerji, U.; Basu, B.; Melero, I.; Calvo, E.; Cassier, P. A.; Drilon, A.; Fong, P. C.; more...
    The Oncologist (2025)

    Fulltext@MSK | Save
  • Larotrectinib compared with real-world non-tropomyosin receptor kinase inhibitor therapies in patients with tropomyosin receptor kinase fusion cancer
    Journal Article

    Brose, M. S.; Westphalen, C. B.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A.; Subbiah, V.; more...
    JCO Precision Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
    Journal Article

    Hong, D. S.; Xu, R. H.; Shen, L.; Dierselhuis, M. P.; Orbach, D.; McDermott, R.; Italiano, A.; Tahara, M.; Bernard-Gauthier, V.; Neu, N.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Diverse ERBB2/ERBB3 activating alterations and coalterations have implications for HER2/3-targeted therapies across solid tumors
    Journal Article

    Liu, D.; Jee, J.; Drilon, A.; Heilmann, A. M.; Allen, J. M.; Schrock, A. B.; Keller-Evans, R. B.; Li, B. T.
    Cancer Research Communications (2025)

    Fulltext@MSK | Save
  • Dual Targeting of RET and SRC to Treat RET-Positive Non-Small Cell Lung Cancer
    Meeting Abstract

    Son, J.; Rix, L. L. R.; Fang, B.; Welsh, E. A.; Drilon, A.; Koomen, J. M.; Cocco, E.; Rix, U.
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy outcomes of larotrectinib by prior therapy and performance status in patients with TRK fusion lung cancer
    Meeting Abstract

    Moreno Garcia, V.; Drilon, A.; Kummar, S.; Lin, J. J.; Tan, D. S. W.; Rieke, D. T.; Dubashi, B.; Kunhiparambath, H.; Burcoveanu, D. I.; Neu, N.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Genetic ancestry-based differences in biomarker-based eligibility for precision oncology therapies
    Journal Article

    Arora, K.; Suehnholz, S. P.; Zhang, H.; Ostrovnaya, I.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Brannon, A. R.; Bandlamudi, C.; Ladanyi, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions
    Review

    Desilets, A.; Repetto, M.; Yang, S. R.; Drilon, A.
    Cancer (2025)

    Fulltext@MSK | Save